Glioblastoma is an aggressive brain tumor that affects an estimated 12,000 people per year, with poor overall prognosis and long-term survival rates. Northwestern Medicine scientists are at the forefront of leading-edge investigations to discover the roots of glioblastoma’s origins, and to pinpoint innovative new treatments to attack this deadly disease.
A recent Northwestern Medicine study found that patients with glioblastoma responded better or worse to immunotherapy depending on the presence of certain mutations in their tumors.
A Northwestern Medicine study has demonstrated the role of dopamine in the progression of glioblastoma and suggests that targeting the neurotransmitter may slow cancer growth.
Northwestern Medicine scientists have identified a gene, called isocitrate dehydrogenase 3-alpha, that promotes tumors in grade IV glioblastoma, according to a study published in Science Advances.
Northwestern Medicine investigators are leading a Specialized Program of Research Excellence (SPORE) in brain cancer with a special emphasis on glioblastoma.
Scientists discovered the regulatory role of the enzyme CDK5 in an aggressive form of brain cancer and successfully halted tumor growth by inhibiting it.
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation therapy.
Scientists used a new approach to identify a promising therapeutic target for glioblastoma, which was previously overlooked in traditional approaches.
Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating glioblastoma.
Northwestern Medicine scientists have demonstrated that an enzyme called IDH1 plays a significant role in cancer progression and may be a target for novel drug therapies.
An investigational neural stem cell therapy that works with a common cold virus to seek out and attack malignant glioma is being tested at Northwestern Medicine in a phase I clinical trial.